180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b ... - BioSpace

Retrieved on: 2022-04-30 15:13:15

Tags for this article:

Life Sciences

Medical specialties

Health sciences

Monoclonal antibodies

Clinical research

Design of experiments

Drug discovery

Pharmaceutical industry

TNF inhibitor

Clinical trial

Tumor necrosis factor

Adalimumab

Wellcome Trust

United States

Click the tags to see associated articles and topics

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b ... - BioSpace. View article details on HISWAI: https://www.biospace.com/article/releases/180-life-sciences-and-university-of-oxford-announce-publication-of-positive-phase-2b-dupuytren-s-disease-study-results-in-the-lancet-rheumatology/

Excerpt

(NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that ...

Article found on: www.biospace.com

View Original Article